IL17A and psoriasis: In line with the immunosuppressive therapy approach, further studies have shown that targeted therapy reduced cardiovascular mortality in rheumatoid arthritis (IL-6, TNF-α, and IL-17A cascades) (Pasceri and Yeh, 1999; Choy, 2012), lupus erythematosus (IL-17A signaling) (Crispín and Tsokos, 2010), and psoriasis (IL-17/IL-23) (Di Cesare et al., 2009; Papp et al., 2012).